A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

Background & Aims: Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-...

Full description

Bibliographic Details
Main Authors: Frederik Nevens, Thierry Gustot, Pierre-François Laterre, Luc L. Lasser, Lyudmil E. Haralampiev, Victor Vargas, Desislava Lyubomirova, Agustin Albillos, Mustapha Najimi, Sébastien Michel, Ivaylo Stoykov, Noelia Gordillo, Yelena Vainilovich, Virginie Barthel, Nathalie Clerget-Chossat, Etienne M. Sokal
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:JHEP Reports
Subjects:
Alcoholic liver disease
Stem cell
Liver regenerative medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555921000677

Internet

http://www.sciencedirect.com/science/article/pii/S2589555921000677

Similar Items